x

Spero Therapeutics, Inc. (Nasdaq:SPRO)

Health Care/Life Sciences • Biotechnology
CIK 1701108
Company

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Address
675 Massachusetts Avenue
14th floor
Cambridge, Massachusetts 02139
Employees
35
Stock Info
Close
$1.7400
Day Range
1.6600 - 1.7501
52 Week Range
0.9900 - 1.9950
Average volume
205.09K
Short Interest
564K (02/29/24)
% of Float Shorted
1.59%
Market Cap
$87.98M
Revenue
$48.58M
Net Income
-$46.42M
2020 Sales Growth
N/A
Rev. per Employee
$2.036M
P/E Ratio
181.25
EPS
$0.0096
Yield
N/A
Dividend
N/A
Ex-Dividend Date
N/A
Key Executives
Board Of Directors
Chairman
Ankit A Mahadevia MD, MBA
President, Chief Executive Officer & Director
Satyavrat Shukla CFA, MBA
Independent Director
Frank E Thomas CPA
Independent Director
Scott T Jackson MBA
Lead Independent Director
Patrick Volkert Vink MD, MBA
Independent Director
Milind S Deshpande PhD
Independent Director
Kathleen Tregoning
Independent Director
Cynthia Smith MBA
Independent Director
John C Pottage Jr., MD
SEC filings
DateFormEvent
14 Nov, 2024 8-K
14 Nov, 2024 10-Q
14 Nov, 2024 SC 13G/A
12 Nov, 2024 4
29 Oct, 2024 8-K
10 Sep, 2024 8-K
29 Aug, 2024 4
29 Aug, 2024 4
29 Aug, 2024 4
6 Aug, 2024 4
5 Aug, 2024 10-Q
5 Aug, 2024 S-8
5 Aug, 2024 8-K
3 Jun, 2024 8-K
30 May, 2024 4
30 May, 2024 4
30 May, 2024 4
30 May, 2024 4
30 May, 2024 4
30 May, 2024 4
30 May, 2024 4
30 May, 2024 4
15 May, 2024 8-K
15 May, 2024 10-Q
16 Apr, 2024 DEFA14A
16 Apr, 2024 ARS
16 Apr, 2024 DEF 14A
29 Mar, 2024 8-K
22 Mar, 2024 EFFECT
20 Mar, 2024 UPLOAD
20 Mar, 2024 CORRESP
15 Mar, 2024 S-8
15 Mar, 2024 S-3
13 Mar, 2024 10-K
13 Mar, 2024 8-K
14 Feb, 2024 SC 13G
9 Feb, 2024 8-K CEO Change
5 Feb, 2024 4
5 Feb, 2024 4
5 Feb, 2024 4
5 Feb, 2024 4
5 Feb, 2024 4
5 Feb, 2024 4
5 Feb, 2024 144
8 Jan, 2024 8-K
5 Jan, 2024 8-K
4 Jan, 2024 4
2 Jan, 2024 8-K
15 Nov, 2023 3
15 Nov, 2023 4
13 Nov, 2023 S-8
13 Nov, 2023 S-8
13 Nov, 2023 10-Q
13 Nov, 2023 8-K
1 Nov, 2023 8-K
16 Oct, 2023 8-K/A
10 Oct, 2023 4
10 Oct, 2023 8-K
10 Oct, 2023 4
10 Oct, 2023 4
10 Oct, 2023 4
10 Oct, 2023 4
10 Oct, 2023 4
10 Oct, 2023 4
10 Oct, 2023 4
15 Sep, 2023 4
1 Sep, 2023 DEF 14A
1 Sep, 2023 ARS
30 Aug, 2023 4
30 Aug, 2023 4
30 Aug, 2023 4
30 Aug, 2023 4
29 Aug, 2023 144
22 Aug, 2023 PRE 14A
10 Aug, 2023 10-Q
10 Aug, 2023 S-8
10 Aug, 2023 8-K
3 Aug, 2023 4
31 Jul, 2023 8-K
24 Jul, 2023 3
14 Jun, 2023 4
14 Jun, 2023 8-K CEO Change
11 May, 2023 8-K
11 May, 2023 10-Q
30 Mar, 2023 10-K
30 Mar, 2023 8-K
30 Mar, 2023 S-8
14 Feb, 2023 SC 13G/A
14 Feb, 2023 SC 13G/A
6 Feb, 2023 4
3 Feb, 2023 4
3 Feb, 2023 4
3 Feb, 2023 4
3 Feb, 2023 4
3 Feb, 2023 4
1 Feb, 2023 8-K
20 Jan, 2023 SC 13D/A
19 Jan, 2023 CT ORDER
9 Jan, 2023 8-K
5 Jan, 2023 4
5 Jan, 2023 4
15 Nov, 2022 D
14 Nov, 2022 3
14 Nov, 2022 10-Q
14 Nov, 2022 SC 13D/A
14 Nov, 2022 S-8
14 Nov, 2022 8-K
8 Nov, 2022 8-K
3 Oct, 2022 SC 13G/A
26 Sep, 2022 4
22 Sep, 2022 8-K
19 Sep, 2022 4
19 Sep, 2022 4
19 Sep, 2022 4
19 Sep, 2022 4
19 Sep, 2022 4
19 Sep, 2022 8-K
19 Sep, 2022 4
19 Sep, 2022 4
14 Sep, 2022 3
14 Sep, 2022 4
6 Sep, 2022 8-K
30 Aug, 2022 4
10 Aug, 2022 8-K
10 Aug, 2022 10-Q
5 Aug, 2022 DEFA14A
5 Aug, 2022 DEF 14A
8 Jul, 2022 SC 13G
1 Jul, 2022 8-K
27 Jun, 2022 8-K
7 Jun, 2022 8-K
16 May, 2022 8-K
16 May, 2022 10-Q
3 May, 2022 8-K
28 Apr, 2022 4
7 Apr, 2022 8-K
31 Mar, 2022 10-K
31 Mar, 2022 4
31 Mar, 2022 8-K
16 Mar, 2022 4
9 Mar, 2022 SC 13G/A
2 Mar, 2022 4
23 Feb, 2022 4
16 Feb, 2022 8-K
14 Feb, 2022 SC 13G/A
14 Feb, 2022 SC 13G/A
3 Feb, 2022 4
3 Feb, 2022 4
3 Feb, 2022 4
3 Feb, 2022 SC 13G/A
3 Feb, 2022 4
3 Feb, 2022 4
3 Feb, 2022 4
1 Feb, 2022 4
26 Jan, 2022 4
25 Jan, 2022 8-K
25 Jan, 2022 SC 13G/A
20 Jan, 2022 4
19 Jan, 2022 8-K
12 Jan, 2022 4
7 Jan, 2022 4
7 Jan, 2022 4
7 Jan, 2022 4
4 Jan, 2022 8-K
3 Jan, 2022 4
29 Dec, 2021 4
16 Dec, 2021 CT ORDER
12 Nov, 2021 4
10 Nov, 2021 10-Q
10 Nov, 2021 8-K
2 Nov, 2021 4
28 Oct, 2021 8-K
14 Oct, 2021 3
12 Oct, 2021 8-K
4 Oct, 2021 4
30 Sep, 2021 8-K
20 Sep, 2021 S-8
16 Sep, 2021 SC 13D/A
15 Sep, 2021 4
10 Sep, 2021 4
1 Sep, 2021 4
30 Aug, 2021 4
30 Aug, 2021 4
30 Aug, 2021 8-K
30 Aug, 2021 4
30 Aug, 2021 4
30 Aug, 2021 4
30 Aug, 2021 4
27 Aug, 2021 4
24 Aug, 2021 4
18 Aug, 2021 4
18 Aug, 2021 4
18 Aug, 2021 8-K
18 Aug, 2021 4
18 Aug, 2021 4
18 Aug, 2021 4
18 Aug, 2021 4
18 Aug, 2021 4
5 Aug, 2021 10-Q
5 Aug, 2021 8-K
14 Jul, 2021 D
9 Jul, 2021 SC 13G
6 Jul, 2021 DEF 14A
1 Jul, 2021 8-K
25 Jun, 2021 PRE 14A
6 May, 2021 8-K
6 May, 2021 10-Q
29 Mar, 2021 EFFECT
24 Mar, 2021 CORRESP
23 Mar, 2021 10-K/A
17 Mar, 2021 UPLOAD
11 Mar, 2021 10-K
11 Mar, 2021 S-8
11 Mar, 2021 8-K
11 Mar, 2021 S-3
16 Feb, 2021 SC 13D/A
16 Feb, 2021 SC 13G/A
16 Feb, 2021 SC 13G/A
10 Feb, 2021 SC 13G/A
10 Feb, 2021 4
5 Feb, 2021 8-K
4 Feb, 2021 4
3 Feb, 2021 4
3 Feb, 2021 4
3 Feb, 2021 4
3 Feb, 2021 4
2 Feb, 2021 SC 13G
2 Feb, 2021 SC 13G/A
19 Jan, 2021 8-K
6 Jan, 2021 4
6 Jan, 2021 4
6 Jan, 2021 4
6 Jan, 2021 4
5 Jan, 2021 4
5 Jan, 2021 3
Last update:2024-03-12 12:02:51.163335

Sign Up to Subscribe